There are over 80000 deaths yearly in the United States alone that have urinary tract infections listed as the original source of infection. UTIs are one of the most common infections, and they cost the US healthcare system over 3 billion USD per year. There is no effective prevention of UTIs on the market, and the majority of UTIs are caused by the bacterium E. coli. At Baxiva, we are preventing UTIs using a next-generation vaccine. Our vaccine helps your body to recognize the outer surface of the bacteria, which serves as its invisibility cloak. By recognizing the bacteria, the immune system can now fight bacteria as soon as they try to invade the body. We are three founders: Giorgia Greter, Tim Keys, and Christoph Rutschmann, with a passion for developing the next generation of vaccines
Location: Switzerland
Total raised: $3M
Investors 1
| Date | Name | Website |
| 25.06.2025 | Venture Ki... | venturekic... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.08.2025 | - | $3M | CARB-X |
Mentions in press and media 1
| Date | Title | Description |
| 22.08.2025 | Baxiva secures $3 million to advance antibacterial vaccines | Escherichia coli (E. coli) is the leading cause of urinary tract infections, a frequent cause of neonatal sepsis, and is among the leading causes of antimicrobial resistance-associated deaths globally. One approach to tackle this is with m... |